Virtual Library
Start Your Search
Meifeng Ye
Author of
-
+
P2.01 - Advanced NSCLC (Not CME Accredited Session) (ID 950)
- Event: WCLC 2018
- Type: Poster Viewing in the Exhibit Hall
- Track:
- Presentations: 1
- Moderators:
- Coordinates: 9/25/2018, 16:45 - 18:00, Exhibit Hall
-
+
P2.01-131 - Apatinib as an Alternative for Advanced Non-Small Cell Lung Cancer (ID 11784)
16:45 - 18:00 | Author(s): Meifeng Ye
- Abstract
Background
Methylsulfonic apatinib showed promising efficacy for the treatment of non–small-cell lung cancer (NSCLC) as one of the TKIs which specifically inhibits VEGFR-2. We aimed to assess the efficacy of apatinib in each lines of treatment to patients with advanced/metastatic NSCLC.
a9ded1e5ce5d75814730bb4caaf49419 Method
We retrospectively analyzed variables and outcomes of patients with advanced NSCLC, who had received apatinib between January 1, 2016 and April 30, 2018, including: 5 patients of first line treatment, 16 second line treatment, 20 third line treatment and 6 fourth and fifth line treatment.
4c3880bb027f159e801041b1021e88e8 Result
The most frequent treatment-related adverse events were hypertension, proteinuria, hand-foot skin reaction and hemoptysis. Among the 47 cases included in the final analysis, the median progression-free survival among patients was 5.66 months specialized in: 0-24.0 months in first line treatment, 0-10.0 in second line treatment, 2.0-10.0 in third line treatment and 0.6-5.4 months in fourth and fifth line treatment. The median overall survival time for apatinib were 25.97 months, 21.4-28.5 months in third line treatment and 0-64.9 months in fourth and fifth line treatment. No significance was found in either PFS and OS among lines of treatment, histology and EGFR mutation status.
Figure 1 PFS and OS of apatinib in different lines of treatment
8eea62084ca7e541d918e823422bd82e Conclusion
The results indicate the administration of apatinib could be used as an alternative for advanced/metastatic NSCLC patients.
6f8b794f3246b0c1e1780bb4d4d5dc53